Next Article in Journal
Molecular Docking and Dynamics Simulation Revealed Ivermectin as Potential Drug against Schistosoma-Associated Bladder Cancer Targeting Protein Signaling: Computational Drug Repositioning Approach
Next Article in Special Issue
Colonic Diverticulosis and Non-Alcoholic Fatty Liver Disease: Is There a Connection?
Previous Article in Journal
Percutaneous Navigation under Local Anesthesia for Computed Tomography-Guided Microwave Ablation of Malignant Liver Lesions Located in the Hepatic Dome
Previous Article in Special Issue
Association between the Severity of Nonalcoholic Fatty Liver Disease and the Risk of Coronary Artery Calcification
Review

Non-Alcoholic Fatty Liver Disease and COVID-19–Two Pandemics Hitting at the Same Time

Department of Gastroenterology and Hepatology, University Hospital Centre Rijeka, School of Medicine, University of Rijeka, 51000 Rijeka, Croatia
*
Authors to whom correspondence should be addressed.
Academic Editor: Ludovico Abenavoli
Medicina 2021, 57(10), 1057; https://doi.org/10.3390/medicina57101057
Received: 10 September 2021 / Revised: 29 September 2021 / Accepted: 1 October 2021 / Published: 3 October 2021
(This article belongs to the Special Issue Non-alcoholic Fatty Liver Disease – from Bench to the Bedside)
The COVID-19 pandemic was and still is a global burden with more than 178,000,000 cases reported so far. Although it mainly affects respiratory organs, COVID-19 has many extrapulmonary manifestations, including, among other things, liver injury. Many hypotheses have been proposed to explain direct and indirect impacts of the SARS-CoV-2 virus on the liver. Studies have shown that around 15–30% of patients with COVID-19 have underlying liver disease, and 20–35% of patients with COVID-19 had altered liver enzymes at admission. One of the hypotheses is reactivation of an underlying liver disease, such as non-alcoholic fatty liver disease (NAFLD). Some studies have shown that NAFLD is associated with severe COVID-19 and poor outcome; nevertheless, other studies showed no significant difference between groups in comparing complications and clinical outcomes. Patients with NAFLD may suffer severe COVID-19 due to other comorbidities, especially cardiovascular diseases. The link between NAFLD and COVID-19 is not clear yet, and further studies and research are needed. View Full-Text
Keywords: COVID-19; liver injury; metabolic-associated fatty liver disease; metabolic syndrome; non-alcoholic fatty liver disease COVID-19; liver injury; metabolic-associated fatty liver disease; metabolic syndrome; non-alcoholic fatty liver disease
Show Figures

Figure 1

MDPI and ACS Style

Vranić, L.; Radovan, A.; Poropat, G.; Mikolašević, I.; Milić, S. Non-Alcoholic Fatty Liver Disease and COVID-19–Two Pandemics Hitting at the Same Time. Medicina 2021, 57, 1057. https://doi.org/10.3390/medicina57101057

AMA Style

Vranić L, Radovan A, Poropat G, Mikolašević I, Milić S. Non-Alcoholic Fatty Liver Disease and COVID-19–Two Pandemics Hitting at the Same Time. Medicina. 2021; 57(10):1057. https://doi.org/10.3390/medicina57101057

Chicago/Turabian Style

Vranić, Luka, Anja Radovan, Goran Poropat, Ivana Mikolašević, and Sandra Milić. 2021. "Non-Alcoholic Fatty Liver Disease and COVID-19–Two Pandemics Hitting at the Same Time" Medicina 57, no. 10: 1057. https://doi.org/10.3390/medicina57101057

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop